Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab vs sorafenib in first-line unresectable hepatocellular carcinoma
CTR20170882Phase 3Completed
- Sponsor
- BeiGene
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by BeiGene. Started Jan 2018; status: completed.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20170882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170882.